4-(1H-咪唑-4-基)苯甲腈 | 34443-07-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(1H-咪唑-4-基)苯甲腈
• 英文名称: 4-(1H-imidazol-4-yl)benzonitrile
• 英文别名: 4-(1H-imidazol-5-yl)benzonitrile
• CAS: 34443-07-7
• 化学式: C₁₀H₇N₃
• mdl: MFCD08669134
• 分子量: 169.186
• InChiKey: IGUVSJNPHFWESU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  4-(1H-咪唑-4-基)苯甲腈 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-2-(6-butyl-2-(4-(4-cyanophenyl)-1H-imidazol-1-yl)pyrimidin-4-ylamino)-N-(3-ethoxypropyl)-4-methylpentanamide
  参考文献：
  名称：

  Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists

  摘要：

  An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the oral bioavailability. Potent and orally available CXCR2 antagonists are herein reported. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.028
• 作为产物：
  描述：

  2-溴-4'-氰基苯乙酮 以 甲醇 、 formamide 为溶剂， 以55%的产率得到4-(1H-咪唑-4-基)苯甲腈
  参考文献：
  名称：

  Heterocyclic derivatives which inhibit Factor Xa

  摘要：

  这项发明涉及公式(I)和(Ia)的杂环衍生物，或其药用盐，具有抗血栓和抗凝血性能，并因此在治疗人类或动物的方法中有用。该发明还涉及制备这些杂环衍生物的方法，含有它们的药物组合物，以及它们在制造用于产生抗血栓或抗凝血效果的药物的药物中的使用。

  公开号：

  US06395731B1

文献信息

• [EN] UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS<br/>[FR] COMPOSÉS D'URÉE ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME FAAH
  申请人：BIAL PORTELA & Cª S A

  公开号：WO2015016728A1

  公开（公告）日：2015-02-05

  A compound having Formula (I): wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methylsulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

  具有以下化学式（I）的化合物：其中：R1从氢、卤素、羟基和C1-4烷氧基中选择；R2从氢、卤素、羟基和C1-4烷氧基中选择；R3是C1-4烷基；R4是芳基，其被从OSO2NH2、NHCONH2、NHSO2NH2、NHSO2C1-4烷基和CONH2中选择的基团取代；n为0或1；或其药学上可接受的盐；前提是该化合物不是N-(1-苄基哌啶-4-基)-N-甲基-4-(4-(磺胺氨基)苯基)-1H-咪唑-1-羧酰胺或N-(1-苄基哌啶-4-基)-N-甲基-4-(3-(甲磺酰氨基)苯基)-1H-咪唑-1-羧酰胺。该化合物可用作脂肪酸酰胺水解酶的抑制剂。
• [EN] PESTICIDAL COMPOSITIONS<br/>[FR] COMPOSITIONS PESTICIDES
  申请人：DOW AGROSCIENCES LLC

  公开号：WO2011017504A1

  公开（公告）日：2011-02-10

  The present invention concerns novel heteroaryl-N-aryl thiosemicarbazones and their use in pest control, as insecticides and acaπcides This invention also includes preparation of the pesticide compositions containing the compounds, and methods of controlling insects using the compounds

  这项发明涉及新颖的杂环基-N-芳基硫脲类化合物及其在害虫控制中的应用，作为杀虫剂和杀螨剂。该发明还包括含有这些化合物的杀虫剂组合物的制备，以及利用这些化合物控制昆虫的方法。
• [EN] SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] IMIDAZOLE CARBOXAMIDES SUBSTITUÉS ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：BIAL BIOTECH INVEST INC

  公开号：WO2021055612A1

  公开（公告）日：2021-03-25

  The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

  这项发明提供了替代咪唑羧酰胺及相关化合物，含有这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗患者的医疗障碍，例如癌症、溶酶体贮积症、神经退行性疾病、炎症性疾病等的方法。
• PESTICIDAL COMPOSITIONS
  申请人：Crouse Gary D.

  公开号：US20090209476A1

  公开（公告）日：2009-08-20

  The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.

  这份文件中披露的发明涉及杀虫剂领域及其在控制害虫方面的应用。披露了一种具有以下结构的化合物。
• IDO inhibitors
  申请人：NewLink Genetics Corporation

  公开号：US09174942B2

  公开（公告）日：2015-11-03

  Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R1, R4, and R5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.

  目前提供的是按照化学式(I)或(II)提供的化合物以及含有这些化合物的药物组合物，其中R1、R4和R5在此有定义。这些化合物和组合物可用于调节吲哌醇胺2,3-二氧化酶的活性；治疗吲哌醇胺2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于抑制吲哌醇胺-2,3-二氧化酶酶活性的医疗状况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制。